30.03
0.04 (0.13%)
| Previous Close | 29.99 |
| Open | 29.86 |
| Volume | 5,813,077 |
| Avg. Volume (3M) | 3,017,040 |
| Market Cap | 17,693,165,568 |
| Price / Earnings (TTM) | 11.82 |
| Price / Earnings (Forward) | 10.09 |
| Price / Sales | 7.89 |
| Price / Book | 1.95 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| TTM Dividend Yield | 2.80% |
| Profit Margin | 50.53% |
| Operating Margin (TTM) | 130.17% |
| Diluted EPS (TTM) | 2.54 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | 654.30% |
| Total Debt/Equity (MRQ) | 74.16% |
| Current Ratio (MRQ) | 1.54 |
| Operating Cash Flow (TTM) | 2.80 B |
| Levered Free Cash Flow (TTM) | -2.12 B |
| Return on Assets (TTM) | 5.69% |
| Return on Equity (TTM) | 17.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Royalty Pharma plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 13.17% |
| % Held by Institutions | 72.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Siguler Guff Advisers, Llc | 30 Sep 2024 | 3,391,754 |
| 52 Weeks Range | ||
| Median | 40.00 (33.20%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 25 Oct 2024 | 40.00 (33.20%) | Buy | 26.95 |
No data within this time range.
| TTM Dividend Yield | 2.80% |
| 5Y Average Dividend Yield | 2.07% |
| Payout Ratio | 32.68% |
| Expected Next Dividend Payment | Jun 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 21 Feb 2025 | 09 Jan 2025 | 10 Mar 2025 | 0.22 Cash |
| 15 Nov 2024 | 11 Oct 2024 | 10 Dec 2024 | 0.21 Cash |
| 16 Aug 2024 | 17 Jul 2024 | 13 Sep 2024 | 0.21 Cash |
| 16 May 2024 | 17 Apr 2024 | 14 Jun 2024 | 0.21 Cash |
| 15 Feb 2024 | 19 Jan 2024 | 15 Mar 2024 | 0.21 Cash |
| 16 Nov 2023 | 16 Oct 2023 | 15 Dec 2023 | 0.2 Cash |
| 17 Aug 2023 | 17 Jul 2023 | 15 Sep 2023 | 0.2 Cash |
| 18 May 2023 | 17 Apr 2023 | 15 Jun 2023 | 0.2 Cash |
| 15 Feb 2023 | 09 Jan 2023 | 15 Mar 2023 | 0.2 Cash |
| 17 Nov 2022 | 17 Oct 2022 | 15 Dec 2022 | 0.19 Cash |
| 18 Aug 2022 | - | 15 Sep 2022 | 0.19 Cash |
| 19 May 2022 | 18 Apr 2022 | 15 Jun 2022 | 0.19 Cash |
| 17 Feb 2022 | 06 Jan 2022 | 15 Mar 2022 | 0.19 Cash |
| 18 Nov 2021 | 15 Oct 2021 | 15 Dec 2021 | 0.17 Cash |
| 19 Aug 2021 | 16 Jul 2021 | 15 Sep 2021 | 0.17 Cash |
| 19 May 2021 | 15 Apr 2021 | 15 Jun 2021 | 0.17 Cash |
| 18 Feb 2021 | 08 Jan 2021 | 15 Mar 2021 | 0.17 Cash |
| 19 Nov 2020 | 15 Oct 2020 | 15 Dec 2020 | 0.15 Cash |
| 14 Sep 2020 | 02 Sep 2020 | 30 Sep 2020 | 0.15 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.220 | 1 | 0.73 |
| 2024 | 0.840 | 4 | 3.29 |
| 2023 | 0.800 | 4 | 2.85 |
| 2022 | 0.760 | 4 | 1.92 |
| 2021 | 0.680 | 4 | 1.71 |
| 2020 | 0.300 | 2 | 0.60 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |